Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Str8Shuteron Aug 17, 2020 12:15pm
114 Views
Post# 31418115

RE:Summary of the AGM Meeting

RE:Summary of the AGM MeetingGood summary.  I will endeavor to re-review the presentation later and will supplement your points below with any other key take-aways that I see.  FYI, the word that JHT used was THRIVE (vs. strive).     :-)

BTW, are you and Brad129 somehow related?  Just curious, since you signed off below as Brad. 

GLTA!


AngelMan92 wrote:

Please do yourself a favor and do your own DD and watch the Webcast in it's full form from the Sedar site document's link.

 

Stagezero is FIRST AND FOREMOST a cancer screening company
 
Aristotle has been in development for 15 years
 
COVID has impacted the healthcare system heavily (revenue has dipped heavily as a result of haulting the health systems)
 
Testing in Arizona, where the positive rate is extremely high
 
Stage considers itself as a company that can not only survive this pandemic but strive in light of it.
 
Stage has a turnaround of 2-3 days (often 2 days) on COVID tests so they are building many clients
 
No pop up Covid sites as they are not profitable and often enough illegal
 
Stage foresees their heavy demand to continue until the end of 2021 (24 months)
 
Aristotle is still set to launch at year's end
 
"Don't trust Stockhouse, they make things up" HAHAHAHH
 
Their current partners work with the ideology "come for COVID, stay for CANCER"
 
The company is ramping up and continuing to strive
 
Alot of their orders are paid, in the bank
 
The other cancer tests on the market, do not have specificity (they only tell you what cancer it is at a 50% chance as opposed to Arist. 99%)
 
Aristotle will take over Colonsentry as it is even able to tell you whether you are Stage 1,2,3, or 4.
 
When you have a product that is better for the health and the cost structure, then we have EVERYONE's attention
 
We have done 1 million$ in revenue in 6 weeks of Q3
 
No Projections are possible right now as things are just too volatile, so we will be updated as things go on
 

Let me know if I missed anything,

Brad



Bullboard Posts